Document text
Principal Investigator: Monica Shokeen
Organization: WASHINGTON UNIVERSITY
Fiscal Year: 2024
Award: $592,217
Funding agency: National Cancer Institute
Multiple myeloma (MM) is the 2nd most common, age related, hematological malignancy with an estimated
30,000 new cases and 13,000 deaths per year. Patients with upfront refractory disease progress fast, and those
that enter remission eventually die as a consequence of relapsed disease. To increase patient survival, clinicians
need new ways of selecting effective and durable therapies for relapsed and refractory MM patients. Antibody
(Ab) based treatments that target cluster of differentiation 38 (CD38), a transmembrane protein consistently
expressed in MM cells, is a promising therapy for relapsed and refractory MM patients. Currently, there are three
CD38 targeted monoclonal Abs (mAbs) in the clinic for MM patients, daratumumab, isatuximab and MOR-202.
These Abs are safe, well tolerated and show remarkable efficacy in ~30% of myeloma patients. It is unknown
why the majority of remaining patients do not respond to CD38 targeted mAb therapy and why there is such
variability between patients. Functionally, CD38 is a pleiotropic antigen that acts as an enzyme as well as a
receptor. The extracellular enzymatic component of CD38 is responsible for the metabolism of nicotinamide
adenine dinucleotide (NAD) to downstream Ca2+ signaling molecules. There is growing evidence that variability
in CD38 targeted therapy response in MM cells could in large part be contributed to the changes in its NAD
enzymatic activity. Here, we posit that while CD38 expression is important, the monitoring of CD38 enzymatic
activity in concert with spatiotemporal imaging is key to linking MM response to CD38 targeted therapies. We
propose to address this question using Positron Emission Tomography (PET), which is a powerful molecular
imaging tool that can be directly applied to quantify receptor expression and functional activity in vivo, non-
destructively and longitudinally. We have shown that PET imaging of CD38 antigen on MM cells is feasible using
the radiolabeled CD38 mAb daratumumab. A limitation of this approach however is that Abs are not suited for
longitudinal imaging studies due to their long biological half-life. High-affinity peptide based small molecule
imaging agents can effectively overcome these limitations since they are rapidly taken up by tumor tissue while
being promptly cleared from non-target organs in vivo. Despite the unmet need, there is a paucity of CD38
targeted small molecule peptide based PET probes for MM. Using innovative phage display technology, we will
develop new CD38 targeted peptide-based PET imaging probes that are specific for enzymatically activate CD38
conformation. Furthermore, in highly relevant biological systems, we will evaluate molecular pathways as well
as spatial relationships that govern MM-associated CD38 expression. The specific aims are: (1) Aim 1a. Identify
and validate changes in CD38 expression and enzymatic activity before and after CD38 targeted therapies in
human mouse models of MM. Aim 1b. Evaluate spatiotemporal CD38 expression based on PET imaging. (2)
Aim 2. Develop, evaluate and optimize novel high affinity CD38 targeted peptide PET probes.
In summary, the current proposal is innovative and potentially clinically transformative since it seeks to identify
those MM patients who are most sensitive and most resistant to anti-CD38 monoclonal immunotherapy.
Terms: <18-FDG><18F- FDG><18FDG><2 Fluoro 2 deoxy D glucose><2-Fluoro-2-deoxyglucose><65 and older><65 or older><65 years of age and older><65 years of age or more><65 years of age or older><65+ years><65+ years old><> 65 years><Address><Affinity><African ancestry><African descent><Age><Aged 65 and Over><Antibodies><Antibody Therapy><Antigenic Determinants><Antigens><Beetles><Benchmarking><Best Practice Analysis><Binding><Binding Determinants><Biological><Bone marrow biopsy><Cell Body><Cells><Cessation of life><Clinic><Clinical><Clinical Treatment Moab><Coleoptera><Combined Modality Therapy><DNA Molecular Biology><Data><Death><Diagnostic tests><Dihydronicotinamide Adenine Dinucleotide><Diphosphopyridine Nucleotide><Disease remission><Engraftment><Enzyme Gene><Enzymes><Epitopes><Family Medical History><Family Medical History Epidemiology><Family history of><Generations><Goals><Green Fluorescent Proteins><Half-Life><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Human><Image><Imaging Device><Imaging Instrument><Imaging Tool><Immune><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunotherapy><Integral Membrane Protein><Intermediary Metabolism><Intrinsic Membrane Protein><Knowledge><Lead><Link><Luciferase Immunologic><Luciferases><Malignant Hematologic Neoplasm><Malignant lymphoid neoplasm><Metabolic Processes><Metabolism><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Biology><Molecular Configuration><Molecular Conformation><Molecular Interaction><Molecular Stereochemistry><Monitor><Monoclonal Antibodies><Monoclonal Antibody Therapy><Multimodal Therapy><Multimodal Treatment><Multiple Myeloma><Murine><Mus><Nadide><Nicotinamide adenine dinucleotide><Nicotinamide-Adenine Dinucleotide><Order Coleoptera><Organ><PET><PET Scan><PET imaging><PETSCAN><PETT><Pathogenesis><Pathway interactions><Patients><Pb element><Peptides><Phage Display><Phenotype><Plasma-Cell Myeloma><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Proteins><Rad.-PET><Radiolabeled><Radiopharmaceutical Compound><Radiopharmaceuticals><Receptor Protein><Recurrent disease><Refractory><Refractory Disease><Relapse><Relapsed Disease><Remission><Resistance><Risk Factors><SCID Mice><Sampling Errors><Severe Combined Immunodeficient Mice><Signaling Molecule><Spatial Distribution><Technology><Testing><Therapeutic Uses><Therapeutic antibodies><Tracer><Transmembrane Protein><Transmembrane Protein Gene><Tumor Cell><Tumor Tissue><Universities><Virginia><above age 65><after age 65><age 65 and greater><age 65 and older><age 65 or older><age > 65><age associated><age correlated><age dependent><age linked><age of 65 years onward><age related><age specific><aged 65 and greater><aged 65+><aged ≥65><ages><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><benchmark><biologic><biological systems><combination therapy><combined modality treatment><combined treatment><conformation><conformational><conformational state><conformationally><conformations><extracellular><fluorodeoxyglucose><heavy metal Pb><heavy metal lead><human model><human old age (65+)><imaging><imaging agent><imaging probe><imaging study><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><in vivo><innovate><innovation><innovative><longitudinal imaging><lymphoid cancers><lymphoid malignancy><mAB-based therapy><mAb therapy><mAb-based therapeutics><mAbs><male><model of human><molecular imaging><molecule imaging><monoclonal Abs><mouse model><multi-modal therapy><multi-modal treatment><murine model><myeloma><myelomatosis><neoplastic cell><novel><old age><over 65 years><pathway><patient variability><patient variation><peptide aminoacid sequence><peptide sequence><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><protein aminoacid sequence><quantitative imaging><radioactive drugs><radiolabeling><radiologically labeled><radiotherapeutic drugs><receptor><receptor expression><resistant><response><response to therapy><response to treatment><serial imaging><sex><small molecule><spatial relationship><spatiotemporal><standard of care><subcutaneous><subdermal><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic response><therapy response><treatment response><treatment responsiveness><tumor><uptake><variability between patients><variation between patients><≥65 years>